Bagsværd, Denmark, 25 September 2023 – On 10 August 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under the programm
Collaboration will apply Valo’s Opal Computational Platform™ and real-world patient dataset to enable the discovery and development of novel cardiometabolic drug programmes Novo Nordisk licenses three preclinical drug discovery programmes in cardiovascular diseases discovered and developed by Valo using the Opal Computational Platform™ Valo will receive an upfront payment and a potential near-term milestone payment, totalling 60 million US dollars, and is eligible to receive milestone payments f
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's one clear-cut stock-split stock that's notably cheaper than the rest.